Apricus Biosciences, a pharmaceutical company, has appointed Steve Martin as senior vice president (SVP) and chief financial officer (CFO), replacing Mark Westgate, who will serve as a consultant to the company during a transition period.
Martin, a certified public accountant (CPA), brings over 25 years of financial leadership to Apricus Bio, with significant expertise in growing public companies in a variety of industries, including the life sciences. Since 2008, he served as SVP and CFO of BakBone Software, a software company. He also served as interim chief executive officer (CEO) over the final 10 months with BakBone and through the successful sale of the company that was completed in January 2011.
From 2005 to 2007, Martin served as CFO of Stratagene Corporation, specialising in the development, manufacture and marketing of specialised research and clinical diagnostic products. Martin’s experience also includes the position of controller with Gen-Probe, a life sciences company, as well as 10 years with the public accounting firm of Deloitte & Touche.
Martin holds a BS in Accounting from San Diego State University. In 2011, he was awarded the San Diego Business Journal’s ‘CFO of the Year Award’ for medium public companies. He is also the former president and a member of the board of directors of the Financial Executives International San Diego Chapter.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.